Dear Editor:
Measuring the Value of Colonoscopists' Performance
Dear Editor:
The article by Gohel at al 1 not only addresses the relevant relationship between polypectomy rate (PR) and adenoma detection rate (ADR) but also provides important clinical insights into the value of colonoscopy performance among a large cohort of endoscopists. With the growing emphasis on value-based payment, the value of clinicians' performance is now subject to greater scrutiny. In healthcare, value is defined as quality of care adjusted for cost. 2, 3 In the context of colonoscopy practice, one approach to expressing value is the ratio of adenoma detection, a measure of quality, to polyp detection, which can serve as a surrogate estimate of procedure cost. The principal cost components of a colonoscopy are technical facility charge, endoscopist professional charge, pathology charge, and anesthesia charge. 4 In endoscopy units in which sedation is administered by the endoscopist, thereby avoiding any additional anesthesiologist professional fee, the number of histology specimen containers used, which generally correlates closely with PR, represents the major source of variable costs per procedure. Therefore, with these assumptions in mind, the ratio of ADR to PR can be used to estimate the value of a colonoscopist's performance, ie, quality/cost.
In the article by Gohel et al, 1 the overall mean ADR/PR ratio for the 65 colonoscopists studied was 58%, with a broad variation from 0% to 97% and standard deviation of 20%. The coefficient of variation (ratio of the standard deviation to the mean) was 34%; by convention, a coefficient of variation >15% represents broad spread, thereby indicating a high level of variation in value of endoscopists' performances. Figure 1 illustrates the relationship between ADR and PR for the author's study group. The horizontal line separates endoscopists with ADR above and below the mean (25%). As shown, the cohort of endoscopists who achieve an acceptable level of quality (ADR >25%) can be further classified as higher value or lower value performers on the basis of whether they have high PR (thereby incurring high pathology charges) or low PR (incurring lesser pathology charges).
Although there are many measures of colonoscopy quality other than ADR and many contributors to cost other than pathology charges, the data provided by Gohel et al 1 illustrate one approach to numerically quantifying the value of colonoscopy performance. With the introduction of the Affordable Care Act and the shift toward value-based reimbursement in place of a fee-for-service model of payment, value measurement, not just in endoscopy but in all aspects of clinical care, will assume increasing importance.
GAVIN C. HAREWOOD, MD, MBA, MSc, FASGE Department of Gastroenterology and Hepatology
Beaumont Hospital Dublin, Ireland
